GAITHERSBURG, Md., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business developments, financial outlook for full year 2016, and revenue guidance for the first quarter of 2016.
This conference call can be accessed live by telephone or through Emergent’s website:
|Live Teleconference Information:|
Dial in number: (855) 766-6521
International dial in: (262) 912-6157
| Live Webcast Information:|
and select the “Investors” section
Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: edge.media-server.com/m/p/9j5eeynk.
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
CONTACT: Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 BurrowsR@ebsi.com Media Contact: Tracey Schmitt Lintott Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 SchmittT@ebsi.com